Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial

The Lancet

Volumn 388, Issue 10044, 2016, Pages 576-585

  Atkins, Harold L ^a,b,c   Bowman, Marjorie ^a,b   Allan, David ^a,b,c   Anstee, Grizel ^b   Arnold, Douglas L ^d,e   Bar Or, Amit ^d   Bence Bruckler, Isabelle ^b,c   Birch, Paul ^f   Bredeson, Christopher ^a,b,c   Chen, Jacqueline ^d,g   Fergusson, Dean ^a,c   Halpenny, Mike ^f   Hamelin, Linda ^b   Huebsch, Lothar ^b,c   Hutton, Brian ^a   Laneuville, Pierre ^h,i   Lapierre, Yves ^d   Lee, Hyunwoo ^d   Martin, Lisa ^f   McDiarmid, Sheryl ^b   O'Connor, Paul ^j   Ramsay, Timothy ^a,c   Sabloff, Mitchell ^b,c   Walker, Lisa ^b,c   Freedman, Mark S ^a,b,c   more..

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e NEURORX RESEARCH   (Canada)

^f CANADIAN BLOOD SERVICES   (Canada)

^g LERNER RESEARCH INSTITUTE   (United States)

^h MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

ⁱ MCGILL UNIVERSITY   (Canada)

^j ST MICHAEL'S HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; BUSULFAN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; FILGRASTIM; GADOLINIUM; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; MITOXANTRONE; PREDNISONE; THYMOCYTE ANTIBODY; THYROTROPIN; THYROXINE; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY;

ABLATION THERAPY; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOIMMUNE DISEASE; BRAIN ATROPHY; CANADA; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DRUG DOSE REDUCTION; EXPANDED DISABILITY STATUS SCALE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; HUMAN HERPESVIRUS 6; HYPERTHYROIDISM; HYPOTHYROIDISM; IMMUNOABLATION; IMMUNOTHERAPY; KLEBSIELLA INFECTION; LIVER VENOOCCLUSIVE DISEASE; LONG TERM CARE; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; STEM CELL MOBILIZATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; VERRUCA PLANTARIS; VIRUS PNEUMONIA; ADOLESCENT; AUTOTRANSPLANTATION; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; BUSULFAN; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 84986265706     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30169-6     Document Type: Article

References (38)

1. 1 Friese, M, Schattling, B, Fugger, L, Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol 10 (2014), 225–238.
2. 2 Wingerchuk, DM, Carter, JL, Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc 89 (2014), 225–240.
3. 3 Atkins, H, Hematopoietic SCT for the treatment of multiple sclerosis. Bone Marrow Transplant 45 (2010), 1671–1681.
4. 4 Coles, AJ, Twyman, CL, Arnold, DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380 (2012), 1829–1839.
5. 5 Bowen, JD, Kraft, GH, Wundes, A, et al. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results. Bone Marrow Transplant 47 (2012), 946–951.
6. 6 Mancardi, GL, Sormani, MP, Di Gioia, M, et al. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. Mult Scler 18 (2012), 835–842.
7. 7 Weinshenker, BG, Rice, GP, Noseworthy, JH, Carriere, W, Baskerville, J, Ebers, GC, The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 114 (1991), 1045–1056.
8. 8 Kurtzke, JF, Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983), 1444–1452.
9. 9 Paty, DW, Noseworthy, JH, Ebers, GC, Diagnosis of Multiple Sclerosis. Paty, D, Ebers, GC, (eds.) Multiple sclerosis, 1998, FA Davis.
10. 10 Fazekas, F, Offenbacher, H, Fuchs, S, et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 38 (1988), 1822–1825.
11. 11 Atkins, H, Freedman, M, Immune ablation followed by autologous hematopoietic stem cell transplantation for the treatment of poor prognosis multiple sclerosis. Methods Mol Biol Clift NJ 549 (2009), 231–246.
12. 12 Bearman, SI, Appelbaum, FR, Buckner, CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6 (1988), 1562–1568.
13. 13 Kappos, L, Lechner-Scott, J, Lienert, C, Neurostatus, Training CD-ROM for a standardized neurological examination and assessment of Kurtzke's functional systems and EDSS for MS patients. https://www.neurostatus.net/training/, 2000.
14. 14 Chen, JT, Collins, DL, Freedman, MS, Atkins, HL, Arnold, DL, Local magnetization transfer ratio signal inhomogeneity is related to subsequent change in MTR in lesions and normal-appearing white-matter of multiple sclerosis patients. Neuroimage 25 (2005), 1272–1278.
15. 15 Smith, SM, Zhang, Y, Jenkinson, M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17 (2002), 479–489.
16. 16 Darlington, PJ, Touil, T, Doucet, J-S, et al. Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol 73 (2013), 341–354.
17. 17 Roxburgh, RHSR, Seaman, SR, Masterman, T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 64 (2005), 1144–1151.
18. 18 De Stefano, N, Giorgio, A, Battaglini, M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 74 (2010), 1868–1876.
19. 19 De Stefano, N, Stromillo, ML, Giorgio, A, et al. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry 87 (2016), 93–99.
20. 20 Edan, G, Comi, G, Le Page, E, Leray, E, Rocca, MA, Filippi, M, Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J Neurol Neurosurg Psychiatry 82 (2011), 1344–1350.
21. 21 Le Page, E, Leray, E, Taurin, G, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 79 (2008), 52–56.
22. 22 Alajlan, A, Alfadley, A, Pedersen, K-T, Transfer of vitiligo after allogeneic bone marrow transplantation. J Am Acad Dermatol 46 (2002), 606–610.
23. 23 Fagnoni, FF, Lozza, L, Zibera, C, et al. Cytotoxic chemotherapy preceding apheresis of peripheral blood progenitor cells can affect the early reconstitution phase of naive T cells after autologous transplantation. Bone Marrow Transplant 31 (2003), 31–38.
24. 24 Pasquini, MC, Devine, S, Mendizabal, A, et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transpl. J Clin Oncol 30 (2012), 3194–3201.
25. 25 Burt, RK, Balabanov, R, Han, X, et al. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. JAMA 313 (2015), 275–284.
26. 26 Nash, RA, Hutton, GJ, Racke, MK, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol 72 (2015), 159–169.
27. 27 Mancardi, GL, Sormani, MP, Gualandi, F, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology 84 (2015), 981–988.
28. 28 Menon, S, Shirani, A, Zhao, Y, et al. Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry 84 (2013), 1192–1198.
29. 29 Krasulová, E, Trneny, M, Kozák, T, et al. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Mult Scler 16 (2010), 685–693.
30. 30 Fassas, A, Kimiskidis, VK, Sakellari, I, et al. Long-term results of stem cell transplantation for MS: a single-center experience. Neurology 76 (2011), 1066–1070.
31. 31 Shevchenko, JL, Kuznetsov, AN, Ionova, TI, et al. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis. Exp Hematol 40 (2012), 892–898.
32. 32 Burman, J, Iacobaeus, E, Svenningsson, A, et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatry 85 (2014), 1116–1121.
33. 33 Muraro, P, Pasquini, M, Atkins, H, et al. Long-term outcomes after autologous haematopoietic cell transplantation for multiple sclerosis: a joint study from the Center for International Blood and Marrow Research (CIBMTR) and the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant, 48, 2013, S1.
34. 34 Burt, RK, Cohen, B, Russell, E, et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 102 (2003), 2373–2378.
35. 35 Alix, JJP, Blackburn, DJ, Sokhi, D, Craven, I, Sharrack, B, Snowden, JA, Autologous hematopoietic stem cell transplantation following pulsed cyclophosphamide in a severely disabled patient with malignant multiple sclerosis. J Neurol 260 (2013), 914–916.
36. 36 Rocca, M, Mondria, T, Valsasina, P, et al. A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive multiple sclerosis. AJNR Am J Neuroradiol 28 (2007), 1659–1661.
37. 37 Farge, D, Labopin, M, Tyndall, A, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 95 (2010), 284–292.
38. 38 Pasquini, MC, Voltarelli, J, Atkins, HL, et al. Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant 18 (2012), 1471–1478.